Imeka Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 7

Imeka General Information

Description

Developer of a brain imaging system designed to offer insights into neuroinflammation, demyelination and axonal loss. The company's technology offers MRI high-standing structure as well as a PET (positron emission tomography) or SPECT (single-photon emission computed tomography) preclinical cardiac analysis service, enabling pharmaceutical companies to understand brain connectivity specifically white matter imaging.

Contact Information

Website
www.imeka.ca
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 195, Belvédère Nord
  • Bureau 201
  • Sherbrooke, Quebec J1H 4A7
  • Canada
+1 (819)
Primary Industry
Diagnostic Equipment
Other Industries
Outcome Management (Healthcare)
Corporate Office
  • 195, Belvédère Nord
  • Bureau 201
  • Sherbrooke, Quebec J1H 4A7
  • Canada
+1 (819)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Imeka Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 24-Oct-2023 Completed Generating Revenue
7. Accelerator/Incubator 01-Jan-2018 Completed Generating Revenue
6. Later Stage VC 12-Dec-2017 Completed Generating Revenue
5. Debt - General 01-Apr-2017 Completed Generating Revenue
4. Early Stage VC Completed Startup
3. Accelerator/Incubator 01-Jan-2015 Completed Startup
2. Debt - General Completed Startup
1. Accelerator/Incubator Completed Startup
To view Imeka’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Imeka Patents

Imeka Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260112031-A1 Harmonization of diffusion magnetic resonance imaging Pending 21-Oct-2024
WO-2026088076-A1 Harmonization of diffusion magnetic resonance imaging Pending 21-Oct-2024
US-20250384556-A1 Automatic quality control of image diffusion processing Pending 17-Jun-2024
US-12573498-B2 Determination of white-matter neurodegenerative disease biomarkers Active 16-Jul-2021
US-20230022257-A1 Determination of white-matter neurodegenerative disease biomarkers Active 16-Jul-2021 G16H30/40
To view Imeka’s complete patent history, request access »

Imeka Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Imeka Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital Minority
Creative Destruction Lab Accelerator/Incubator
Canada Economic Development for Quebec Regions Government Minority
Desjardins Capital PE/Buyout Minority
Fonds Innovexport Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Imeka FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process